Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Abstract SARS-CoV-2 has the capacity to evolve mutations that escape vaccine- and infection-acquired immunity and antiviral drugs. A variant-agnostic therapeutic agent that protects against severe disease without putting selective pressure on the virus would thus be a valuable biomedical tool that w...

Full description

Bibliographic Details
Main Authors: Matthew Gagne, Barbara J. Flynn, Christopher Cole Honeycutt, Dillon R. Flebbe, Shayne F. Andrew, Samantha J. Provost, Lauren McCormick, Alex Van Ry, Elizabeth McCarthy, John-Paul M. Todd, Saran Bao, I-Ting Teng, Shir Marciano, Yinon Rudich, Chunlin Li, Shilpi Jain, Bushra Wali, Laurent Pessaint, Alan Dodson, Anthony Cook, Mark G. Lewis, Hanne Andersen, Jiří Zahradník, Mehul S. Suthar, Martha C. Nason, Kathryn E. Foulds, Peter D. Kwong, Mario Roederer, Gideon Schreiber, Robert A. Seder, Daniel C. Douek
Format: Article
Language:English
Published: Nature Portfolio 2024-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-51046-w

Internet

https://doi.org/10.1038/s41467-024-51046-w

Similar Items